Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)

BACKGROUND: Acceleration of negative respiratory conversion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with coronavirus disease 2019 (COVID-19) might reduce viral transmission. Nirmatrelvir/ritonavir is a new antiviral agent recently approved for treatment of COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongyan, Gao, Menghan, You, Hailong, Zhang, Peng, Pan, Yuchen, Li, Nan, Qin, Ling, Wang, Heyuan, Li, Dan, Li, Yang, Qiao, Hongmei, Gu, Lina, Xu, Songbai, Guo, Weiying, Wang, Nanya, Liu, Chaoying, Gao, Pujun, Niu, Junqi, Cao, Jie, Zheng, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384507/
https://www.ncbi.nlm.nih.gov/pubmed/35870128
http://dx.doi.org/10.1093/cid/ciac600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384507/
https://www.ncbi.nlm.nih.gov/pubmed/35870128
http://dx.doi.org/10.1093/cid/ciac600

Ejemplares similares